Transgene Announces Participation at Upcoming Investor Events

STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:

Transgene (Paris: TNG) today announced that management will participate in the upcoming investor events outlined below:

• Rodman & Renshaw 18th Global Investment Conference: September 12 & 13, 2016 - New York, USA

• Mid Cap Event: October 5 & 6, 2016 - Paris, France
• Actionaria: November 18 & 19, 2016 - Paris, France
• Natixis Mid Cap Conference: November 22, 2016 - Paris, France

Next financial communication:

Financial results for the first six months of 2016 and business update:September 5, 2016 after market close

About TransgeneTransgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at www.transgene.fr.

Follow us on Twitter: @TransgeneSA

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005930/en/

Transgene:
Lucie Larguier, +33 (0)3 88 27 91 04
Director Corporate Communications & IR
[email protected]
or
Media contacts:
Citigate Dewe Rogerson
David Dible / Marine Perrier, + 44 (0)20 7638 9571
[email protected]

Source: Transgene

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Halozyme adds biotech executive Appelhans to its board
• Nvidia and Broadcom earnings: TD Cowen says earnings won’t settle big questions